|
|
Human Growth HormonePublished by: Datamonitor Published: Oct. 29, 2002 - 29 Pages Table of ContentsOverview Introduction Pending DRIVERS AND TRENDS The global Human Growth Hormone (hGH) market was worth approximately $1.5 billion in 2001. Due to the high cost of treatment, there is a considerable incentive for generic biologics companies to develop low cost generic forms of hGH. As the efficacy and side effects profiles of hGH products are virtually identical, products are defined through the innovativeness of the delivery technology and the formulation of the drug. Additional drivers behind current product uptake include the approved indications of the drug, the marketing strength of the company, and the cost of treatment. INTRODUCTION This section provides an overview of the disease, defining the specific patient populations eligible to receive hGH therapy, and outlining disease incidence and prevalence. MARKET OVERVIEW What is the value of the hGH market, which companies have hGH products, and what are their current marketing strategies? This section covers: Sales data and market growth of the top 6 hGH products in 2000 and 2001 Review of the products and companies within the hGH market A comparison of drug delivery technology Review of approved drug indications and treatment costs DEVELOPMENT OPPORTUNITIES What are the current opportunities within the hGH market? This section provides an overview of the key opportunities available for companies to realize the patient potential and drive market growth, including: A review of the current hGH product pipeline Evaluation of companies developing hGH products, including identification of out licensing opportunities Insight into opportunities for market penetration and growth DATASETS Table 1: Sales of currently marketed hGH products, 2000-01 Table 2: Approved indications of hGH products Table 3: Comparison of hGH product prices, 2001 Table 4: US patent expiry dates of hGH products Table 5: The hGH pipeline Table 6: 2001 cost of hGH treatment Figure 1: Global market share of hGH products, 2001 Figure 2: Comparison of drug delivery systems on the hGH market AbstractIntroduction: The global Human Growth Hormone (hGH) market, was worth approximately $1.5 billion in 2001. Traditionally a market with a small number of key players, the development of generic products and innovation of currently marketed products is causing market leaders to reassess current market strategy. Datamonitor's Human Growth Hormone analysis provides a comprehensive overview of the current hGH market, and the product pipeline, and reviews strategies that may be utilized to optimize hGH uptake. Scope: * Definition of patient populations, including disease incidence and prevalence * Analysis of 2001 sales data for the six major hGH products * Identification of out licensing opportunities and strategic recommendations formarket growth * Comparisons between drug administration techniques, approved indications and treatment costs * Overview of the hGH pipeline, including analysis of companies involved in developing hGH products. Report Highlights: Brand differentiation through innovations in delivery technology will be a critical success factor in this largely homogenous market. Growth in the Human Growth Hormone market is being driven by expansion in the number of approved indications and increasing generic competition. Reasons to Purchase: * Promoting physician awareness of price differences between products may drive the uptake of less expensive less well-known products. * Gaining approval for additional indications is one of the market strategies that has secured the success of Genotropin as market leader.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||